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Choroid PlexusThe number of disease models that involve an aspect of blood–brain barrier (BBB) dysregulation have
increased tremendously. The main factors contributing to this expansion have been an increased number of
diseases in which the BBB is known to be involved, an increase in the known functions of the BBB, and an
increase in the number of models and tools with which those diverse functions can be studied. In many
cases, the BBB may be a target of disease; current thinking would include hypertensive encephalopathy and
perhaps stroke in this category. Another category are those diseases in which special attributes of the BBB
may predispose to disease; for example, the ability of a pathogen to cross the BBB often depends on the
pathogen's ability to invoke transcytotic pathways in the brain endothelial or choroid plexus cell. Of special
interest are those diseases in which the BBB may be the primary seat of disease or play a major role in the
onset or progression of the disease. An increasing number of diseases are so categorized in which BBB
dysfunction or dysregulation plays a major role; this review highlights such roles for the BBB including those
proposed for Alzheimer's disease and obesity.
Published by Elsevier B.V.1. Introduction
Models of blood–brain barrier (BBB)-disease interactions have
increased tremendously in number in the last two decades. Although
there are many reasons for this, three main trends are largely res-
ponsible for the increase. First, there are more diseases which are
thought to involve the BBB. At the same time, the explosion in animal
models for any given disease have further enhanced this reason. Second,
there are more and better models for studying the BBB. This allows
functions tobe investigated thatpreviously couldnot bemodeled. Third,
the BBB has more functions than were previously appreciated. These
functions can be studied and their dysfunction can participate in disease
processes inwayswhichwere not imagined even a few years ago. These
three aspects are considered in more detail below.
The trends and future directions can be better appreciated by
examining the state of BBB models 3–4 decades ago. Good sources
for this are Rapoport's classic “Blood–Brain Barrier in Physiology and
Medicine” published in 1976 [1] and Bradbury's “The Concept of a
Blood–Brain Barrier” published in 1979 [2]. These books remain
excellent sources for understanding the fundamentals of the BBB,
but also provide snap shots of the status of BBB disease models some
30+ years ago. Many things have not changed: models of multiple
sclerosis and stroke are still of major interest, debate continues
about whether immune cells cross the BBB by penetrating betweenB.V.or through endothelial cells, and issues related to drug delivery to
the CNS present major challenges. But many things have changed
also: there are many more models of stroke as well as models of
components of stroke (such as hypoxia/reoxygenation), immune
cells are now widely believed to cross the BBB under normal
physiologic conditions and not just during brain infection, and drug
delivery has become still more challenging with the discovery of, for
example, efﬂux systems. Diseases most actively modeled in the
1970s were stroke, multiple sclerosis, trauma, cytotoxicity, invasion
by cancer cells and leukemias, brain infections and encephalitides,
convulsions and epilepsy, and hypertensive encephalopathy. BBB
tissues were known to be enzymatically active and to be important
in preventing monoamine transport across the BBB. Methods
available allowed three generic types of studies to be done: the
measure of uptake rates of substances which crossed the BBB very
rapidly, such as hexoses, amino acids, or small lipid soluble
molecules; the study of ﬂuxes of substances which were metabol-
ically stable such as electrolytes; studies of BBB disruption and
edema, often using dye or ﬂuid shift models. The conceptual view of
the functions of the BBB these models helped to deﬁne and exploit
were that of the nutritional and homeostatic regulatory interface,
the lipid permeable cell membrane, and the barrier.2. General themes
The BBB models of diseases can be subdivided into 3 general
categories as to their relation to the disease that they model. The ﬁrst
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aspect of the disease by a mechanism that is clearly not the etiology
of the disease. The purpose of these studies is to investigate the
downstream consequences of the disease feature while recognizing
that upstream events cannot be studied. An example of this model is
induction of type I diabetes mellitus with streptozotocin. Although
streptozotocin induces an insulinopenic hyperglycemic state, the
hallmark of type I diabetes mellitus, streptozotocin is not the common
etiology of diabetes mellitus in humans. As a result, the downstream
consequences of deﬁcient insulin or hyperglycemia can be studied,
but questions related to etiology, predisposition to disease, or genetics
are not easily studied with this model.
A second category is that in which the disease being studied arises
from essentially the same etiology in the model as in humans and
follows essentially the same course. Pure examples of these are rare
and the most useful models. An example in this category is that of
maturity onset obesity in a mouse strain which is not otherwise prone
to obesity. In a version of this model, randomly selected mice are fed
regular chow for an extended period. A subset will tend towards a
higher level of obesity than the average, just as in the human
population. In a variation of this version, a high fat diet and sedentary
conditions will accentuate the differences in body weight, just as
occurs in humans.
A third category of model is that in which the relation between the
etiology of the disease and the inducer of the model are unclear. This
leads to ambiguity as to what extent the model recapitulates the
disease. An example of this is the use of experimental allergic
encephalomyelitis (EAE) to model multiple sclerosis. There are
several EAE models that primarily vary in the method used to induce
disease, but most activate the immune system against components of
the nervous system. As the etiology of multiple sclerosis is unknown,
it is unclear to what degree, if any, the variousmethods used to induce
EAE resemble the etiology of multiple sclerosis.
3. Diseases affecting or involving the BBB
The number of diseases in which the BBB is thought to be affected
has increased dramatically. Included are some of the most important
diseases of Western society such as Alzheimer's disease, obesity,
epilepsy, and diabetes mellitus [3-8]. The role of the BBB in many
diseases has also shifted from being a passive target to an active
participant, even a prime participant, in disease. Two examples of
diseases in which the BBB may play the role of prime participant are
obesity and Alzheimer's disease; these are considered in detail below.
Other models suggesting a primary role for the BBB in disease
states are those relating to immune cell and pathogen penetration of
the BBB. Diseases involving immune inﬁltration are often mistakenly
thought to occur because a disruption of the BBB allows the immune
cells to leak into the brain. It is now clearly understood that immune
cells and brain endothelial cells participate in an elaborate cross talk
termed diapedesis [9]. Passage of immune cells across the BBB
involves activation of both the immune cell and BBB cells [10,11].
Blockade of key receptors on either brain endothelial cells or the
immune cells can halt or retard diapedesis. This is most dramatically
shown by treatment with natalizumab, an antibody that binds to
immune cells to block alpha(4) integrin binding and is effective
against multiple sclerosis.
Multiple sclerosis is a disease in which the BBB plays a major role.
EAE is used as a model of multiple sclerosis [12]. There are several
versions of induction of EAE that produce either relapsing and non-
relapsing disease [13,14]. EAEmodels clearly support a role of the BBB
inmediating onset and progression of disease [15,16]. The EAEmodels
have also been important tools in the investigation of how immune
cells cross the BBB [17]. Work with these models also shows that
disruption of the BBB is secondary to immune cell invasion, not the
other way round [18–20]. Other aspects of BBB function are also likelyaffected by induction of EAE and, presumably, in multiple sclerosis
such as cytokine transport [21]. The EAE model has also served as an
example of how neuroimmune activation can facilitate immune cell
invasion for other conditions and diseases such as spinal cord injury
[22].
HIV-1 invasion of the CNS occurs when immune cells infected with
the virus cross the BBB [23]. Immune cells containing HIV-1 are
activated and more likely to adhere to brain endothelial cells than
non-infected cells [24]. Models of this disease also show that immune
cell invasion produces BBB leakage and disruption rather than the BBB
disruption allowing immune cells to leak into the brain [25]. HIV-1
can also cross the BBB as free virus and does so by interacting in a
complex manner with the cells which constitute the BBB [26,27]. This
complexity occurs not just with initial binding, but with subsequent
interaction with cellular machinery that controls transcytosis [28–31]
Indeed, the neuroAIDS ﬁeld has produced an important example of
how pathogen and BBB cells interact to activate one another and to
forward the progression of disease [24,32]. This interaction has
consequences in addition to the facilitation of passage of pathogen
across the BBB [23,33]. For example, the immune activation induced
by the neuroAIDS process [34] activates other components of the
neurovascular unit, secretions from BBB cells, and alters expression of
p-glycoprotein at the BBB [35–37]. This latter effect, in turn, affects the
delivery of antivirals to the CNS [38,39].
These principles apply to most other neuropathogens which enter
the CNS by crossing the vascular BBB or choroid plexus [40]. That is,
the virus, bacteria, or parasite induces alterations in the BBB function
which facilitate the passage of the agent across the barrier as opposed
to leaking across an already disrupted BBB [41–44]. The agent often
induces cooperation of the BBB, taking over some aspect of endo-
genous machinery.
4. Models of the BBB
The multiplication of models can be illustrated by the increased
number of models for stroke or diabetes mellitus. Stroke models or
models relating to some aspect of stroke have expanded greatly in the
last few decades and demonstrated important changes in BBB tight
junctions in the post-ischemic state [45]. For example, there are
currently ﬁve major categories of ischemic models: embolic middle
cerebral artery occlusion, endovascular ﬁlament middle cerebral
artery occlusion, permanent transcranial middle cerebral artery
occlusion, transient transcranial middle cerebral artery occlusion,
and cerebrocortical photothrombosis. These models are not simply
variants on how to produce the same end point, but have subtle
differences including how the BBB is affected or responds. There are
also “component models” that involve replication of a major aspect of
stroke [46]. For example, hypoxia/reoxygenation models lower the
ambient oxygen to a level and for a time that affects BBB and CNS
function to study the effects of hypoxia. Oxygen levels are then
returned to normal to study effects of reoxygenation, a period when
damage from oxidative stress can occur. In this model, unlike the focal
ischemia models, blood ﬂow does not cease, no physical damage is
done to endothelial cells by a plug or clot, and hypoxia/reoxygenation
is global, not localized. Although stroke involves all of these, hypoxia/
reoxygenation is not a stroke model, but it models a major compo-
nent of stroke. Results may be applicable to other diseases involving
hypoxia or hypoxia with reoxygenation, such as sleep apnea, asthma,
chronic obstructive pulmonary disease, cardiac arrest, and cardiopul-
monary bypass.
Stroke models have also been used to study how drug delivery
mechanismsmay differ in the post-stroke BBB or how potential thera-
peutics affect BBB disruption in stroke [47–49]. Alterations in relevant
BBB transporter systems, such as those for peptides and cytokines, or
expression of other BBB proteins have also been studied in stroke or
stroke-prone models [50–52]. Modeling can lead to therapeutic stra-
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inhibiting brain-to-blood efﬂux systems [53].
Stroke is usually considered a disease associated with aging, but
one form, cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL), occurs in persons under
40 years of age [54]. CADASIL results from a mutation in the Notch3
gene. Although the mutation is throughout the vascular bed, it seems
that only the central nervous system is affected. Mouse and pig
models recapitulate various aspects of the disease, developing a
CADASIL-like picture. Loss of pericytes is prerequisite to the dev-
elopment of altered BBB permeability and hypoperfusion (R Cecchelli,
personal communication). Interestingly, pericyte drop out is also key
to the develop of disruption of the blood–retinal barrier in diabetes
mellitus [55,56].
Most models of diabetes mellitus use streptozotocin which des-
troys the beta cells of the pancreas. This produces an insulinopenic
hyperglycemia and so models type I diabetes mellitus. However, as
discussed below, aspects of the BBB are also affected in obesity. Many
models of obesity are likely also producing animals with insulin
resistance or hyperinsulinemic hyperglycemia. The latter would
model diabetes mellitus type II. These models provide new opportu-
nities to study the effects of type II diabetes mellitus on the BBB.
The BBB can be involved indirectly in models of diseases not
typically thought to have a BBB component. For example, the lyso-
somal storage diseases result from defects in enzyme production,
function, or translocation, allowing the accumulation of various
storage products [57]. Dysfunction of both peripheral tissues and the
CNS occurs with the accumulation of these storage products. In many
of these diseases, normal function can be returned to the peripheral
tissues by treatment with enzyme. However, these enzymes are large
and do not cross the BBB of adults. As such, lysosomal storage diseases
represent a major challenge for CNS drug delivery [58,59]. They also
represent an excellent model for the development of drug delivery
systems for large proteins. Animal models with the enzyme of interest
knocked outwill give a clear signal of clearing of storage productwhen
therapeutic amounts of the enzyme are delivered to the brain. Most
drug development for this disease has concentrated on delivering
enzyme as a cargo attached to some other substance that will cross the
BBB rapidly, the oft-called Trojan horse approach. More recent work
has noted that the perinatal BBB expresses functional mannose-6
phosphate receptor which transports into the brain two enzymes,
GUSB whose deﬁciency causes Sly syndrome and sulfamidase whose
deﬁciency causes Sanﬁlippo syndrome [60,61]. Thus, the brains of
neonates in which these enzymes are knocked out can be successfully
treated by giving peripheral enzyme [62–64]. However, the trans-
porter function is lost with maturity and is virtually absent by
adulthood. Recent work has shown that epinephrine can re-induce
transporter function in adults [65]. Thus, lysosomal storage diseases
may provide an excellent model for the study of transcytotic events
and their induction at the BBB. Recentwork has also suggested that the
BBB is not itself resistant to the pathologies of lysosomal storage
disease (DJ Begley, personal communication). Knockouts for MPS IIIA
have a decreased brain vascular space, altered penetration of diaze-
pam, and increased penetration of glycine. This opens the possibility
that among the targets of these diseases is the BBB itself.
5. Functions of the BBB
Traditional studies have focused on BBB disruption. Classically,
diseases such as multiple sclerosis, stroke/ischemia, trauma, Alzhei-
mer's disease, epilepsy, CNS cancers, hypertensive encephalopathy,
and sepsis have been modeled [21,66–69]. More recently, neuroAIDs,
diabetes mellitus, and chronic pain syndromes have been shown to
have disruptions in the BBB [70–72].
A wide variety of approaches have been used to study BBB dis-
ruption and these have given different aspects to the overall picture.Injection of dyes was the original method used by Erlich in the 1880's
that led eventually to the elucidation of barrier function and was used
for decades [73]. This method has enjoyed a resurgence in use in the
last decade or so, possibly because little special equipment or regu-
latory oversight is needed. The method, however, requires skill and
practice to give reliable results. Main sources of error are inadequate
washout of the vascular space, disruption of the BBB from washout of
the vascular space, or administration of too high a dose of dye. The
latter occurs when the amount of dye given exceeds the binding
capacity of serum albumin. These common errors all act to
overestimate BBB disruption. Ultrastructural studies ultimately
showed the anatomical basis for the BBB [74] and subsequently
showed that most disruptions of the BBB [75] result from increased
vesicular pathways (transcytosis) with or without an accompanying
opening of tight junctions (paracellular pathways). Nevertheless,
many current studies, especially those devoted to use of in vitro
methods, focus on tight junctions. Radioactive studies using a series of
molecular weight markers can often distinguish between disruption
from transcytosis, in which the measure of disruption is similar
regardless of the molecular size of the marker, vs. paracellular
mechanisms, in which smaller molecular weight markers often give
larger measures of disruption [76,77].
In comparison to disruption, other aspects of BBB function during
disease are relatively understudied. This is unfortunate, as it is likely
that these other functions change much more early in the course of
disease and likely are much more relevant to all but the terminal
aspects of disease progression than is disruption. Changes in BBB lipid
composition, receptor binding kinetics and function, transporter
function, immune cell trafﬁcking, enzymatic activity, and secretory
capacity have been shown to change in models of aging, diabetes
mellitus, sepsis, neuroimmune activation, multiple sclerosis, neu-
roAIDS, and Alzheimer's disease [6,9,21,23,78–86]. Changes in
transporter function as central to progression of obesity and
Alzheimer's disease is discussed below, but other important examples
exist. For example, whereas disruption of the BBB begins after several
weeks of streptozotocin-induced diabetes mellitus, the transport of
insulin across the BBB is altered within 72 h [72,87]. Whereas the BBB
can become disrupted in neuroAIDS or with seizures, these conditions
cause alterations in p-glycoprotein expression [88,89]. This, in turn,
alters the ability of anti-virals and anti-epileptic medications to
accumulate within the CNS.
Modeling of many diseases shows that the BBB is involved or
altered on many levels [90]. For example, in neuroAIDS: the BBB is
minimally disrupted [25,42,91]; activation of BBB cells and immune
cells leads to enhanced adhesion of immune cells to the BBB and
enhanced viral entry [25,33,34,92,93]; infected immune cells, free
virus, and viral proteins including the neurotoxic gp120 and TAT cross
the BBB [23,26,33,94,95]; BBB surface glycoprotein composition likely
determines which HIV-1 strains are taken up or transported by the
BBB [29]; BBB efﬂux systems impair the accumulation by the brain of
many antivirals [38,39,96]; BBB secretions and cell surface expression
of immune-active cytokines and chemokines is increased by virus or
viral proteins [32,97,98]. These changes affect many aspects of AIDS
and neuroAIDS including disease initiation and progression, neuroim-
mune activation, and drug delivery. Such multi-level changes in the
BBB also occur in models for diabetes mellitus and sepsis/neuroim-
mune activation.
Another example of the expanded understanding of the sorts of
roles the BBB may play in diseases is provided by epilepsy. Classically,
the BBB has been noted to be disrupted in seizures with such
disruption affected by parameters such as aging and gender [99,100].
More recently, drug delivery has become of great interest with the
realization that an efﬂux system located at the BBB termed p-
glycoprotein retards the accumulation by brain of most anti-seizure
medications [101,102]. Indeed, the some 30% of epileptic patients who
are resistant to anti-seizure medications may be so because of
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been shown that seizure activity increases expression of p-glycopro-
tein at the BBB, thus complicating control of epilepsy [88,89]. Finally,
immune cell-BBB interactions may be key to turning experimental
seizure into epilepsy. Seizure activity induces selectin expression at
the BBB which increases immune cell adhesion and perhaps CNS
trafﬁcking [8]. Blockade of immune cell-BBB adhesion inhibits both
induction of acute seizures and chronic recurrent seizure activity.
6. Diseases caused by the BBB: the case for Alzheimer's and obesity
Diseases in which the BBB plays a central or primary role could be
those in which either the BBB is the original site of pathophysiology or
in which altered BBB function is key to disease progression. Multiple
sclerosis and stroke including CADASIL have been considered above.
To this list can be added De Vivo's disease, which includes familial
seizures andmental retardation resulting fromunderexpression of the
GLUT-1 transporter at the BBB [104]. Encephalopathy occurs when the
BBB is disrupted during hypertensive emergencies; although formerly
thought to be entirely caused by physical disruption from high
pressure,more recent investigations suggest that activity of the renin–
angiotensin–aldosterone system in general and of angiotensin II in
particular may be important. In a broader sense, epilepsy resistance to
anti-seizuremedications, which occurs in about 30% of cases, is caused
by overexpression of p-glycoprotein at the BBB, andCNS infections and
infestations arise because of the ability of the pathogens to interact
with the BBB in a way to negotiate their permeation into the CNS.
Arguments which place the BBB in a causal role in Alzheimer's disease
and obesity are illustrative of the general concepts of this review.
7. Alzheimer's disease
Several hypotheses have been advanced that would involve the
BBB/cerebrovasculature (Table 1) in AD. These include BBB disrup-
tion, defective glucose transport, and release of neurotoxins from the
BBB. One of the most recent hypotheses is the neurovascular
hypothesis [3]. This states that deﬁcient efﬂux of amyloid β peptide
(Aβ) from the brain contributes to its accumulation and toxicity
within the CNS. That Aβ is removed from the CNS by a rapid saturable
efﬂux system has beenwell documented by several laboratories [105–
108]. In addition, Aβ efﬂux is decreased in both transgenic mice and
the SAMP8, a mouse strain with a natural mutation that results in an
age-dependent increase in Aβ and cognitive defects [105,109,110].
Efﬂux of Aβ from brain has been suggested to be mediated by low
density lipoprotein receptor-related protein-1 (LRP-1) and by p-
glycoprotein [107,111–113]. Aβ is a ligand for liver LRP-1 which likely
plays an important role in its clearance from blood. Immunohisto-
chemistry studies show that LRP-1 levels decrease in brains of AD
patients [4]. However, other studies suggest that the relations amongTable 1
Theories relating Alzheimer's disease to the blood–brain barrier and the
cerebrovasculature.
Leaky blood–brain barrier [163]
Tortuous capillary bed [164]
Defective glucose transporters [83]
Microvascularopathy [165]
Cerebrovascular degeneration [166]
Brain endothelium and the release of neurotoxins [82]
Permeation of aluminum–glutamate complexes [167]
Inhibition of brain endothelial cell proliferation [168]
Decreased vitamin B12 transport [169]
Vascular cognitive impairment [170]
Altered insulin transport into brain [171]
Decreased cerebral blood ﬂow [172]
Aβ Formation of ionophores [173]
Neurovascular hypothesis: decreased Aβ efﬂux from brain [4]LRP-1, Aβ, and p-glycoprotein are complex and may involve other
ligands or transporters [106,114]. A model in which LRP-1 at the BBB
was knocked down with antisense given by intracerebroventricular
infusion showed that brain Aβ levels increased about 40% and mice
developed cognitive impairments [115]. These results are consistent
with amajor role in AD for the BBB efﬂux of Aβ by an LRP-1 dependent
system.
Other work has suggested that blood-to-brain transport of blood-
borne Aβ could contribute to brain levels of Aβ with the receptor for
advanced glycation end products (RAGE) acting as the primary
transporter [116,117]. The contribution that circulating Aβ makes to
CNS levels of Aβ is not established and so the role of blood-to-brain
transport is less clear. Findings suggest, however, that just as Aβ efﬂux
is decreased in AD, blood-to-brain transport is increased.
Given the evidence that the BBB transporters are altered to favor
increased inﬂux and decreased efﬂux of Aβ, the question arises as to
what dictates these changes. Isoforms of Aβ are differentially trans-
ported by LRP-1 and with aging in the SAMP8, efﬂux of Aβ1–42 is
more signiﬁcantly lost than efﬂux of Aβ1–40 [105,118]. This would
favor retention of the more toxic form of Aβ1–42 with aging. Dime-
rization and complexing with other LRP-1 ligands also retards Aβ
efﬂux [119]. Models of inﬂammation induced by lipopolysaccharide
also recapitulate the proposed ﬁndings in AD, increasing inﬂux and
decreasing efﬂux of Aβ. Interestingly, administration of the nonste-
roidal antiinﬂammatory drug indomethacin prevents the lipopoly-
saccharide-induced impairment of Aβ efﬂux [120]. This is consistent
with the proposed beneﬁcial role of indomethacin in AD [121,122].
8. Obesity
Obesity is characterized by resistance to leptin, a 16-kDa protein
secreted by fat tissue [123]. Leptin crosses the BBB by way of a
saturable transport system where it interacts with its receptors
located throughout the brain [124]. Most studied of the CNS sites is
the arcuate nucleus. Here, leptin acts through its receptor to inhibit
orexigenic peptides such as neuropeptide Y and orexin and to stimu-
late anorexigenic peptides such as melanocortin [125]. Leptin inhibits
feeding through these mechanisms and also increases caloric expen-
diture. These two factors together result in a decrease in fat mass. As
fat mass decreases, so does leptin levels in blood and the CNS; this, in
turn, decreases anorexia and caloric expenditure. Thus, a negative
feedback loop is formed between adipose tissue and feeding/caloric
expenditure. Resistance to these actions of leptin or an absence of
leptin results in obesity.
Leptin interactions with the BBB have been studied in several
animal models, especially those of obesity. The earliest studies were
those of van Heek et al. and Halaas et al. [126,127] in two models of
obesity–prone mice. These two studies showed that as obesity
increased, these mice passed through a phase of resistance to peri-
pherally administered leptin while remaining sensitive to centrally
administered leptin. This is consistent with a block in the blood-to-
brain transfer of leptin and suggested that failure of transport at the
BBB preceded that of resistance at the arcuate nucleus. Pharmacoki-
netic studies in an obesity of maturity model, the Koletsky rat, and
several other obesity models showed transport of leptin across the
BBB to be decreased in proportion to the degree of obesity [128–131].
Studies with the brain perfusion model showed that leptin resistance
at the BBB is complex, induced by both circulating factors, such as
leptin inducing its own self-inhibition, and longer term factors
inducing down regulation [128,132].
Investigation of transport of leptin across the BBB in various
models has revealed several interesting characteristics. The transport
rate is not static but inﬂuenced by obesity, ovarian factors, starvation,
triglycerides, insulin, glucose, and epinephrine [133–136] . Effects of
lipopolysaccharide, cholecystokinin, and alcohol administration have
also been studied [137–139]. The nature of the BBB transporter pro-
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vascular BBB, the short form of the leptin receptor likely acts as the
leptin transporter. However, the Koletsky rat does not express
functional receptors, yet is still able to transport leptin across the
BBB by a saturable mechanism[131,140,141]. Therefore, there is likely
a leptin transporter at the BBB other than the short form. Megalin has
been proposed as the leptin transporter at the choroid plexus [142].
The role of the BBB in modifying leptin actions in the CNS likely
affects many of leptin's other effects. Leptin has effects on immune
function, bone density, cognition, breathing, reproduction, and other
functions, most mediated through CNS sites [143–150]. Leptin has
receptors throughout the brain aswell, including on non-neuronal cells
such as astrocytes [151], so many of these actions may be mediated
through different CNS locales and cell types. The rate of transport of
leptin across the BBB varies among brain regions [152]. As such, the
regional differences obesity has on transport likely means that obesity
has differential effects on the leptin actions mediated through the CNS.
Leptin also has functioning receptors within the subfornical organ, a
circumventricular organ [153]. Similarly, there is evidence for some
arcuate nucleus neurons projecting into the median eminence [154].
This suggests a dynamic interaction of CNS leptin receptor sites that are
inside and outside the BBB as has been proposed for other peptides and
regulatory proteins such as amylin and interleukin.
BBB interactions with other peptides and proteins related to
feeding and metabolism have been studied in various models of
disease. Starvation, immune activation with lipopolysaccharide, obe-
sity, and hypertriglyceridemicmodels have been used to study ghrlein
or insulin transport [87,155–160]. Urocortin transport across the BBB
is induced by leptin and tumor necrosis factor-alpha administration
[161,162].
9. Conclusions
Our understanding of the BBB continues to evolve. As it does, the
BBB is discovered to be involved evermore intimately in an everwider
array of diseases. This understanding has been greatly fostered and
deﬁned by models of the BBB and models of disease states. As these
models continue to conceptualize the BBB not only as a physical
barrier but also as a regulatory interface between the CNS and blood,
more roles in disease states will likely be discovered. Most exciting are
a series of diseases in which the BBB and its dysfunctions play key
roles to disease onset and progression.
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